A clearer brand for the next partnership.
For a Boston research or life-sciences business, a partnering conversation can bring naming decisions into focus. We help distinguish the identity your company is building from the names attached to individual candidates or projects.
The platform behind the pipeline
A development partner may rename a product while your platform continues to support future work. We help assess which identities deserve continuing attention.
Ready for the commercial conversation
Ownership, licenses, and the way a name appears in public materials all matter. We can help connect those details to the next filing or portfolio decision.
A few questions before we begin.
Does trademark registration mean a health product name has regulatory approval?
No. Federal trademark registration and product regulation are different processes. Trademark review addresses the brand and the claimed goods or services; it is not an approval to market a drug, device, or health service. Identify any separate regulatory naming or marketing questions so appropriate advice can be arranged.
USPTO: trademark, patent, or copyright
Trademark registration and filing guidance
Who should own a university spinout’s trademark application?
Determine the correct legal owner from the facts and relevant agreements before filing. Do not automatically name the researcher, university, investor, or newly formed company without review. The trademark owner may not be the same party that owns or licenses the underlying patent. Ownership mistakes can be difficult or impossible to fix.
USPTO: common application problems
Trademark portfolio and ownership guidance
Should we register the platform name, device name, or company name first?
Prioritize based on actual commercial use, planned launches, clearance results, and budget. These may be distinct marks identifying different goods or services. Bring the naming structure and commercialization sequence to counsel so the filing plan reflects business priorities rather than treating all labels as interchangeable.
USPTO: goods and services
Can a clinical presentation or prototype photo prove trademark use?
Not automatically. A specimen must show qualifying use for the identified goods or services and relevant filing basis. A presentation about future availability or a prototype that has not entered qualifying commerce may be insufficient. Have counsel assess the actual activity and evidence instead of selecting the most polished slide.
USPTO: specimens of use
What happens if the USPTO says our life-sciences brand is descriptive?
The response depends on the wording, goods or services, evidence, and procedural posture. Discuss the refusal and strategic options before relying on a generic argument that competitors use similar terminology. Substantive responses and broader naming or portfolio advice are billed at DBA’s current hourly rates. Registration cannot be guaranteed.
USPTO: strong trademarks
What should a Boston biotech bring to a trademark review before a partnering conference?
Bring the platform and candidate-name chart, proposed slides, expected development milestones, and any existing licenses. Identify what will be announced publicly and which names are confidential. The review can then address the commercial identities rather than merely polish the pitch.
If a development partner renames our candidate, should we stop protecting the platform name?
Evaluate the platform’s continuing role in your research services, collaborations, and future candidates. A partner’s product naming decision does not by itself answer your company’s broader brand priorities. We can scope that portfolio review at current hourly rates.
Substantive advice, substantive office-action responses, and portfolio management are billed at our current hourly rates. Intent-to-use matters follow a separate fee schedule. See pricing and scope.
Let’s talk about your next move by phone or Zoom. Schedule an introductory call.
